Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.
Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK
BMJ Open. 2021 Feb 17;11(2):e043566. doi: 10.1136/bmjopen-2020-043566.
Effervescent, soluble, dispersible formulations contain considerable amounts of sodium. In 2013, we previously confirmed the association between sodium-containing medications and cardiovascular risks. This study aimed to determine the changes in the prescribing pattern in clinical practice following this publication.
A longitudinal cross-sectional study.
Primary care in the UK from 2009 to 2018.
Prescribing information in The Health Improvement Network (THIN) and Prescription Cost Analysis (PCA) databases in the UK.
Prescription rates per 10 000 inhabitants were calculated using the number of prescriptions or the number of drug-using patients over the total number of inhabitants, and the prescription rates were measured at annual intervals. Prescribing trends from 2009 to 2018 were indexed with yearly data from THIN and PCA. Interrupted time series analysis (ITSA) was conducted with monthly data in THIN.
From the THIN database, a total of 3 651 419 prescription records from 446 233 patients were included. The prescribing rate of sodium-containing medications changed from 848.3/10 000 inhabitants in 2009 to 571.6/10 000 inhabitants in 2018. The corresponding figures from PCA data were of 631.0/10 000 inhabitants in 2009 and 423.8/10 000 inhabitants in 2018. ITSA showed the prescribing trend reduced significantly during the postpublication period (prescribing rate: slope change=-0.26; 95% CI -0.45 to -0.07; p=0.009; proportion of patients: slope change=-0.22; 95% CI -0.35 to -0.09; p<0.001), but no change in postpublication level from baseline. The prescribing rates for the non-sodium-containing standard formulations were relatively stable over the study period. The reduction in the proportion of patients using sodium-containing medications was only significant in patients over 45 years old.
The prescribing of sodium-containing medications in the UK primary care has declined significantly during the postpublication period. Changes in the prescribing trends for sodium-containing medications varied across regions of the UK and patient age groups.
泡腾、可溶性、分散性制剂含有大量的钠。2013 年,我们曾证实含钠药物与心血管风险之间存在关联。本研究旨在确定该出版物发表后临床实践中药物处方模式的变化。
纵向的横截面研究。
英国的初级保健。
英国的 The Health Improvement Network(THIN)和 Prescription Cost Analysis(PCA)数据库中的处方信息。
使用处方总数或用药患者总数除以居民总数计算每 10000 居民的处方率,并以年度间隔测量处方率。2009 年至 2018 年的处方趋势索引为 THIN 和 PCA 的年度数据。THIN 中的每月数据进行了中断时间序列分析(ITSA)。
从 THIN 数据库中,纳入了来自 446233 名患者的 3651419 份处方记录。含钠药物的处方率从 2009 年的 848.3/10000 居民降至 2018 年的 571.6/10000 居民。PCA 数据的相应数字为 2009 年的 631.0/10000 居民和 2018 年的 423.8/10000 居民。ITSA 显示,在发布后期间,处方趋势显著降低(处方率:斜率变化=-0.26;95%CI-0.45 至-0.07;p=0.009;患者比例:斜率变化=-0.22;95%CI-0.35 至-0.09;p<0.001),但发布后水平与基线相比没有变化。研究期间,非含钠标准制剂的处方率相对稳定。仅在 45 岁以上的患者中,使用含钠药物的患者比例的减少才具有统计学意义。
英国初级保健中含钠药物的处方量在发布后期间显著下降。含钠药物处方趋势的变化在英国不同地区和不同年龄段的患者中有所不同。